Generic Name and Formulations:
Succimer 100mg; caps.
Recordati Rare Diseases, Inc.
Indications for CHEMET:
Lead poisoning in children with blood lead levels >45micrograms/dL.
May swallow caps whole or put contents onto a small amount of soft food or a spoon and swallow, followed by fruit drink. <12months: not recommended. ≥12months: initially 10mg/kg (or 350mg/m2) every 8 hours for 5 days, then reduce frequency to every 12 hours for 14 more days. Allow at least 14 days between courses unless blood lead levels indicate need for more prompt treatment. Treatment for more than 3 consecutive weeks: not recommended.
Monitor for rebound elevated lead levels by measuring blood levels at least once weekly. Maintain adequate hydration. Monitor renal and hepatic function. Monitor for neutropenia; instruct patients to report any sign of infection or rash. Renal impairment. History of hepatic dysfunction. Find and remove source of lead from environment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Other concomitant chelation therapy (e.g., EDTA): not recommended. False (+) results with nitroprusside test (e.g., Ketostix).
GI upset, elevated serum transaminases, rash, pain, cramps, flu-like symptoms, dizziness, drowsiness, paresthesia; neutropenia, mucocutaneous vesicular eruptions (rare).
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis
- Digital Cognitive Therapy Eases Daytime Effects of Insomnia
- Models Predict Intracerebral Hemorrhage Growth
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience